LizaCoscaVillaruzMD
Oncology • Pittsburgh, PAAssociate Professor, Medicine, University of Pittsburgh School of Medicine
Dr. Villaruz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5150 Centre Avenue
Pittsburgh, PA 15232Phone+1 412-623-7833Fax+1 412-648-6579
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2008 - 2011- UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
University of Maryland School of MedicineClass of 2005
Certifications & Licensure
PA State Medical License 2005 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Detection of Genetic Markers of Lung Cancer Start of enrollment: 1996 Jun 01
- Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
- Single Arm on the Tolerability of Weekly Nab-paclitaxel Start of enrollment: 2013 Jun 25
- Join now to see all
Publications & Presentations
PubMed
- 133 citationsIMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver ...Naoyuki Nogami, Fabrice Barlesi, Mark A. Socinski, Martin Reck, Christian Thomas
Journal of Thoracic Oncology. 2021-10-06 - 251 citationsAntitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai-Hong Ignatius Ou, D. Ross Camidge
Nature Medicine. 2020-01-13 - 1536 citationsFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerDavid P. Carbone, Martin Reck, Luis Paz-Ares, Benjamin C. Creelan, Leora Horn
The New England Journal of Medicine. 2017-06-21
Journal Articles
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung CancerLiza C Villaruz, Mark A Socinski, Molecular Diagnosis & Therapy
Press Mentions
Carboplatin, Pemetrexed, and Atezolizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Untreated Brain MetastasesFebruary 27th, 2023
Regional Delivery of Mesothelin-Targeted CAR T-cell Therapy Creates a Win for Solid TumorsApril 10th, 2019
ASCO 2016 News: Overcoming Resistance in Lung CancerJune 10th, 2016- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
